Davide Bolignano - Concepedia

Author

Davide Bolignano

Also Known As

A. A. Alshal, Bolignano, D., Bolignano, Davide, C. Zoccali, D Bolignano, D. Bolignano, DAVIDE BOLIGNANO, Davide Bolignano, Davide Bolignano (665855), Gregory Braden

402

Publications

9.8K

Citations

H-Index

101

Concepts

All Affiliations

University of Messina Magna Graecia University Istituto di Fisiologia Clinica Azienda Ospedaliera Pugliese Ciaccio University of Pisa

About

Davide Bolignano is an author at University of Messina specializing in medicine, chronic kidney disease, and nephrology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	24	1.6K
2	Health Sciences	6	6	706
3	Public Health	4	4	118
4	Applied Physiology	1	1	395
5	Biochemistry	1	1	40

Davide Bolignano

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Progression of Chronic Kidney Disease Davide Bolignano, Antonio Lacquaniti, Giuseppe Coppolino, Clinical Journal of the American Society of Nephrology	2009	556
Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial Fabio Manfredini, Francesca Mallamaci, Graziella D’Arrigo, Journal of the American Society of Nephrology Randomized Clinical TrialPhysical ActivityDialysis TherapyExercise RehabilitationKinesiology	2016	395
Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Anne Blanchard, Detlef Böckenhauer, Davide Bolignano, Kidney International	2016	344
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, The Lancet GlomerulonephritisActive-controlled Clinical TrialRenal FunctionKidney FailureChronic Kidney Disease	2023	203
Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients Davide Bolignano, Antonio Lacquaniti, Giuseppe Coppolino, Kidney & Blood Pressure Research Glomerular DiseaseRenal PathologyImmunologyRenal InflammationPathology	2009	195
Aldosterone antagonists for preventing the progression of chronic kidney disease Davide Bolignano, Suetonia C. Palmer, Sankar D. Navaneethan, Cochrane Database of Systematic Reviews	2014	188
Neutrophil Gelatinase-Associated Lipocalin in Patients with Autosomal-Dominant Polycystic Kidney Disease Davide Bolignano, Giuseppe Coppolino, Susanna Campo, American Journal of Nephrology Glomerular DiseaseCyst Growth ProcessRenal PathologyImmunologyPathology	2007	153
Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min) Guideline Development Group., Henk J.G. Bilo, Luís Coentrão, Nephrology Dialysis Transplantation	2015	153
Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults Maurizio Gallieni, Markus Hollenbeck, Nicholas Inston, Nephrology Dialysis Transplantation	2019	139

Page 1